Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy.
Hsi-Huei LuNan-Tsing ChiuMu-Hung TsaiPublished in: Annals of nuclear medicine (2024)
Dynamic changes in PSADT were associated with survival in mCRPC patients receiving radium therapy. Comparing interim and baseline PSADT could serve as a valuable marker for determining treatment benefits.